Abbott's spin-off AbbVie to join S&P 100 & 500
Dec 20 (Reuters) - AbbVie Inc, the pharmaceutical company being spun off by Abbott Laboratories, is set to join the Standard and Poor's 100 and 500 indices, S&P Dow Jones Indices said.
AbbVie will replace Dell Inc in the S&P 100 and Federated Investors Inc in the S&P 500.
Abbott Labs will remain in both indices.
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video